Proteasome inhibitors in mantle cell lymphoma

详细信息	查看全文 | 推荐本文 |

• 作者：Beata Holkova ; MD^a ; ^b (Assistant Professor) ; Steven Grant ; MD^a ; ^b ; ^{stgrant@vcu.edu} (Professor ; Associate Director ; Co-Leader)
• 关键词：non-Hodgkin's lymphoma ; proteasome inhibitor ; mantle cell lymphoma ; bortezomib ; carfilzomib
• 刊名：Best Practice Research Clinical Haematology
• 出版年：2012
• 期刊代码：36_15216926
• 类别：med
• 出版时间：June, 2012
• 卷：25
• 期：2
• 页码：133-141
• 文件大小：196 K

摘要

Mantle cell lymphoma (MCL) represents a subtype of non-Hodgkin's lymphoma (NHL) which has a relatively poor prognosis compared to other forms of NHL. Despite multiple options for cytotoxic chemotherapy, attempts to prolong the survival of patients with this disease have not yet met with success. Consequently, the development of targeted approaches to therapy which minimize toxicities has potentially important implications for MCL. Proteasome inhibitors preferentially kill transformed cells through diverse mechanisms. The proteasome inhibitor bortezomib was initially approved for patients with relapsed or refractory multiple myeloma and now has been approved for relapsed or refractory MCL. The introduction of newer proteasome inhibitors with activity in bortezomib-resistant disease and reduced toxicity profiles may yield further benefits. Multiple ongoing studies are building on the known efficacy of proteasome inhibitors in MCL by evaluating combination regimens involving either cytotoxic or targeted therapies, with the ultimate goal of prolonging survival in this patient population.